Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; Department of Surgery, Ponce Health Sciences University, Ponce, Puerto Rico.
Miami Ocular Oncology and Retina (MOOR), Miami, Florida.
Ophthalmol Retina. 2021 Dec;5(12):1181-1186. doi: 10.1016/j.oret.2021.09.008.
Targeted antineoplastic agents and immunotherapies have revolutionized management strategies available for previously refractory cancer. Despite the growing list of pharmacologic agents and indications, many of the currently Food and Drug Administration-approved therapies are associated with ocular adverse effects. Retina specialists and oncologists should be aware of potential side effects because some may be severe and permanent. Although most ocular side effects require conservative treatment without discontinuation of life-preserving therapies, rare severe adverse reactions can be potentially blinding and may warrant an extensive discussion regarding different management strategies, including cessation of life-preserving therapy.
靶向抗肿瘤药物和免疫疗法彻底改变了以前难治性癌症的治疗策略。尽管目前有越来越多的药物和适应证获得了美国食品和药物管理局的批准，但许多治疗方法都与眼部不良反应有关。视网膜专家和肿瘤学家应该了解潜在的副作用，因为有些副作用可能很严重且是永久性的。虽然大多数眼部副作用需要保守治疗而无需停止挽救生命的治疗，但罕见的严重不良反应可能会导致失明，因此需要对不同的治疗策略进行广泛讨论，包括停止挽救生命的治疗。
